Background: Short-term hemoglobin (Hb) variability related to volume status is observed in chronic kidney disease (CKD) patients receiving hemodialysis (HD). Given the lack of studies regarding outcomes according to the day of Hb sampling, the existing guidelines do not strongly recommend regarding measurement timing. Pre-dialysis mid-week sampling (Wednesday and Thursday) is preferable to minimize short-term Hb variability, although numerous HD centers perform early-week sampling (Monday and Tuesday). The different measurement days may influence the prescribed dose of erythropoiesis-stimulating agent (ESA) and related patient outcomes. We investigated changes in Hb levels and ESA doses according to the Hb measurement day among HD patients.
Methods: Starting September 2013, the day for pre-dialysis Hb measurement at the Asan Medical Center was changed from early-week days to mid-week days. This single-center retrospective study evaluated medical records of 92 patients who received maintenance HD between September 2012 and August 2014.
Results: There was no significant difference in the mean Hb levels between early-week days and mid-week days (10.71 ± 0.06 g/dL vs. 10.78 ± 0.47 g/dL, p = 0.105). However, the mean doses of darbepoetin-α on early-week days were higher than those on mid-week days (175.4 ± 72.5 μg/month vs. 163.7 ± 83.6 μg/month, p = 0.022). The mean doses of intravenous iron hydroxide sucrose for early-week measurements were also higher than those for mid-week measurements (623.0 ± 489.0 mg/year vs. 447.0 ± 505.2 mg/year, p = 0.001). The mean interdialytic weight gains were 2.81 ± 0.82 kg on early-week days and 1.99 ± 0.61 kg on mid-week days (p < 0.001).
Conclusions: Compared with early-week measurements, mid-week pre-dialysis Hb measurements were significantly associated with lower ESA doses without a change in Hb levels.
Keywords: Anemia; Chronic kidney disease; Erythropoiesis-stimulating agent; Hemodialysis; Hemoglobin.
Conflict of interest statement
The authors declare that they have no competing interests.
2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney DiseaseY Tsubakihara et al. Ther Apher Dial 14 (3), 240-75. PMID 20609178.The Japanese Society for Dialysis Therapy (JSDT) guideline committee, chaired by Dr Y. Tsubakihara, presents the Japanese guidelines entitled "Guidelines for Renal Anemia …
Individualized Anemia Management in a Dialysis Facility - Long-Term Utility as a Single-Center Quality Improvement ExperienceAE Gaweda et al. Clin Nephrol 90 (4), 276-285. PMID 30049300.Implementation of the individualized ESA dosing algorithm facilitates improvement in Hb maintenance within target, decreases Hb variability and reduces the dose of ESA re …
Anemia Management Trends in Hospital-Based Dialysis Centers (HBDCs), 2010 to 2013GN Coritsidis et al. Clin Ther 36 (3), 408-18. PMID 24582713.These study results support growing evidence that meaningful changes have occurred over the last 3 years in how anemia is clinically managed in US hemodialysis patients. …
Systematic Review of the Impact of Erythropoiesis-Stimulating Agents on Fatigue in Dialysis PatientsKL Johansen et al. Nephrol Dial Transplant 27 (6), 2418-25. PMID 22187314. - ReviewPartial correction of anemia with ESA results in improvement of fatigue among patients on dialysis, most strikingly in those patients with baseline Hb levels <10 g/dL. …
Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 83 [Internet]M Chung et al. PMID 23762920. - ReviewAnemia is a common complication of chronic kidney disease (CKD), which develops early in the course of CKD and becomes increasingly severe as kidney function deteriorates …